Effect of lymphokine-containing sera on adenocarcinoma BW10232 and melanoma B16 in C57BL/6 mice.
Lymphokine-containing sera (LKS) inhibited the growth of adenocarcinoma BW10232 and melanoma B16 in C57BL/L mice. Resistance to tumor growth was conferred by daily injections into the challenge site. The injection of LKS did not provide long-term resistance, inasmuch as termination of treatment permitted resumption of tumor growth at the primary tumor site. Whether LKS exerted a direct or indirect effect on the tumor cells to retard their was not certain.
D000230:Adenocarcinoma / Q000628:therapy*; D000818:Animals; D001769:Blood; D007372:Interferons / Q000627:therapeutic use; D008222:Lymphokines / Q000627:therapeutic use*; D008263:Macrophage Migration-Inhibitory Factors / Q000627:therapeutic use; D008545:Melanoma / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000628:therapy
D008222:Lymphokines; D008263:Macrophage Migration-Inhibitory Factors; D007372:Interferons